topotecan has been researched along with Skin Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, J; Li, C; Wang, C; Wei, N; Yang, H; Zhao, X | 1 |
| Abbruzzese, JL; Ellis, AL; Hess, KR; Loughlin, S; Madden, T; Newman, RA; Raber, MN; Sugarman, SM; Zwelling, LA | 1 |
1 trial(s) available for topotecan and Skin Diseases
| Article | Year |
|---|---|
Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Diarrhea; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Headache; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Skin Diseases; Thrombocytopenia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome; Vomiting | 1996 |
1 other study(ies) available for topotecan and Skin Diseases
| Article | Year |
|---|---|
Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Topics: Ammonium Sulfate; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Carcinoma, Lewis Lung; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Female; Half-Life; Hand-Foot Syndrome; Humans; Injections, Intravenous; Leukemia L1210; Liposomes; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasms; Phosphatidylethanolamines; Polyethylene Glycols; Prostatic Neoplasms; Random Allocation; Rats; Rats, Wistar; Skin; Skin Diseases; Tissue Distribution; Topoisomerase I Inhibitors; Topotecan | 2012 |